Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Debt
Short-term and long-term borrowings combined.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt remains negative
Q1 FY2026 total debt was $0, compared with $0 a year earlier.
Context
- Total debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total debt of $0 is the 10th highest of the 11 companies compared; the peer median is $29.04M.
- Total debt amounts to 0.0% of total assets for NVCT, versus a peer median of 3.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.73B | +91265.7% | -7.6% | 1.7% | |
| Mar 2026 | $345.36M | +18700.2% | +568.3% | 73.1% | |
| Jun 2026 | $252.14M | +336.5% | +33.5% | 33.9% | |
| Mar 2026 | $85.48M | +11.3% | +41.6% | 37.5% | |
| Mar 2026 | $36.51M | -2.6% | +45.3% | 16.8% | |
| Mar 2026 | $21.57M | -4.6% | -4.4% | 2.1% | |
| Mar 2026 | $9.79M | +53.4% | +49.6% | 4.8% | |
| Mar 2026 | $3.3M | +2.6% | -1.5% | 0.8% | |
| Mar 2026 | $1.04M | -2.0% | — | 1.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -76.4% | 0.0% | |
| Peer median (excluding NVCT) | $29.04M | +6.9% | +33.5% | 3.4% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.